Investors Financial Results

Announcements 2017

AGM Notice Announcement

Board Meeting Notice July 27, 2017

Glenmark FPJ Page 10

Glenmark Navshakti Page 8

Glenmark Pharmaceuticals Receives Tentative ANDA Approval For Solifenacin Succinate Tablets, 5 mg and 10 mg

Glenmark's consolidated revenue increased by 6.52% to Rs. 24,571.83 Mn for Q4 FY 2016 -- 17

Q4 FY 2017 Results sheet & Statement of Assets and Liabilities

Q4 FY 2017 Management Discussions and Analysis

Q4 Earnings Concall Invitation May 12, 2017

The Free Press Journal

Intimation regarding NSE board meeting

Statement on Form 483 at the Ankleshwar API plant

Glenmark’s Q3 FY 17 results

Glenmark’s MDA Q3 FY 17

Glenmark’s consolidated revenue increases by 42.55 % to Rs. 25,350.08 Mn for Q3 FY 2016 – 17

J P Morgan Healthcare Conference – presentation

Intimation regarding board meeting

Statement of Investor Complaints for Q3 (F. Y. 2016-17)

Financial Results Icon


Be a part of the new world

About Us - Governance


The principles that govern us

Investors Report Icon

Reports And Presentation

Performance in numbers

About Us Thumbnail

About Us

Leading, integrated, global, research-led organization. Words which define us and our vision to discover a healthier future